Leuprolide
- Generic Name
- Leuprolide
- Brand Names
- Camcevi, Eligard, Fensolvi, Lupaneta Pack 1-month, Lupron, Lupron Depot-ped, Viadur, Zeulide Depot
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N16O12
- CAS Number
- 53714-56-0
- Unique Ingredient Identifier
- EFY6W0M8TG
- Background
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the...
- Indication
Leuprolide is indicated for the treatment of advanced prostate cancer and as palliative treatment of advanced prostate cancer.
It is also used for the treatment of pediatric patients with central precocious puberty (CPP).
...
- Associated Conditions
- Advanced Prostate Cancer, Anemia, Central Precocious Puberty (CPP), Endometriosis
- Associated Therapies
- Palliative Treatment
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 28
- Registration Number
- NCT03298087
- Locations
- 🇺🇸
VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States
🇺🇸VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States
🇺🇸Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Palleos Healthcare GmbH
- Target Recruit Count
- 257
- Registration Number
- NCT03272477
- Locations
- 🇩🇪
Evangelisches Krankenhaus Bethesda Mönchengladbach, Mönchengladbach, Germany
Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 333
- Registration Number
- NCT03209492
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 312
- Registration Number
- NCT03209518
- Locations
- 🇯🇵
Takeda selected site, Tokyo, Japan
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 612
- Registration Number
- NCT03070886
- Locations
- 🇺🇸
Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸MyMichigan Medical Center Saginaw, Saginaw, Michigan, United States
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
- Conditions
- Interventions
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 379
- Registration Number
- NCT03056755
- Locations
- 🇺🇸
Kaiser Permanente Medical Group, Anaheim, California, United States
🇺🇸UCSF, San Francisco, California, United States
🇺🇸University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States
A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT03035032
- Locations
- 🇲🇾
Site MY03002, Batu Caves, Selangor, Malaysia
🇵🇭Site PH04001, Makati City, Metro Manila, Philippines
🇵🇭Site PH04003, Manila, Metro Manila, Philippines
A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 108
- Registration Number
- NCT02993926
- Locations
- 🇨🇳
The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Childrens Hospital of Hunan province, Changsha, Hunan, China
🇨🇳Jiangsu Province Hosptial, Nanjing, Jiangsu, China
Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Kyungpook National University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02974270
- Locations
- 🇰🇷
Cheol Woo Ko, Daegu, Korea, Republic of
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
- Conditions
- Interventions
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3246
- Registration Number
- NCT02941926
- Locations
- 🇺🇸
Ventura County Hematology and Oncology, Oxnard, California, United States
🇺🇸Mid Florida Hematology and Onc Ctr, Orange, Florida, United States
🇺🇸Hope Cancer Center of East Texas, Tyler, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.